Rigel Pharmaceuticals (RIGL)
(Delayed Data from NSDQ)
$15.08 USD
+0.58 (4.00%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $15.07 -0.01 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$15.08 USD
+0.58 (4.00%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $15.07 -0.01 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
Zacks News
Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of -15.65% and 2.98%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Rigel (RIGL) Surges 19.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Rigel (RIGL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rigel (RIGL) delivered earnings and revenue surprises of 83.78% and 13.79%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Profound Medical (PROF) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Profound Medical (PROF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aurinia Pharmaceuticals (AUPH) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Aurinia (AUPH) delivered earnings and revenue surprises of 100% and 4.19%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical (COLL) Soars 10.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Collegium Pharmaceutical (COLL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Rigel Pharmaceuticals (RIGL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Rigel (RIGL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rigel (RIGL) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Rigel (RIGL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Rigel (RIGL) delivered earnings and revenue surprises of -66.67% and 5.58%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ProPhase Labs, Inc. (PRPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
ProPhase Labs (PRPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lyra Therapeutics (LYRA) delivered earnings and revenue surprises of -34.62% and 33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Rigel Pharmaceuticals (RIGL) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Rigel Pharmaceuticals (RIGL) Reports Break-Even Earnings for Q4
by Zacks Equity Research
Rigel (RIGL) delivered earnings and revenue surprises of 100% and 0.26%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
OmniAb, Inc. (OABI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioCryst (BCRX) delivered earnings and revenue surprises of -16.67% and 4.72%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Can Rigel Pharmaceuticals (RIGL) Beat Q4 Earnings Estimates?
by Zacks Equity Research
Rigel Pharmaceuticals' (RIGL) Tavalisse tablet sales are expected to have risen in the fourth quarter, driven by demand growth.
Here's Why You Should Bet on Rigel Pharmaceuticals (RIGL) Now
by Zacks Equity Research
Here, we discuss some reasons why buying Rigel Pharmaceuticals (RIGL) stock now may turn out to be a prudent move.
Here's Why You Should Invest in Aquestive (AQST) Stock Now
by Zacks Equity Research
Here, we discuss some reasons why buying Aquestive Therapeutics (AQST) stock now may turn out to be a prudent move.
Corcept (CORT) Falls on Loss of Korlym Patent Lawsuit to Teva
by Zacks Equity Research
The United States district court for the district of New Jersey rules against Corcept (CORT) in a patent infringement lawsuit against Teva Pharmaceuticals. Stock declines.
Eli Lilly (LLY) Stock Up 57% in 2023: Will the Uptrend Continue?
by Zacks Equity Research
Lilly (LLY) is making rapid pipeline progress in areas like obesity, diabetes and Alzheimer's. Mounjaro and Zepbound are expected to be key top-line drivers for Lilly.
Best Momentum Stock to Buy for December 8th
by Zacks Equity Research
BRSP and RIGL made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 8, 2023.
New Strong Buy Stocks for November 28th
by Zacks Equity Research
AQST, BROS, NSSC, RIGL and RBT have been added to the Zacks Rank #1 (Strong Buy) List on November 28, 2023.
Best Momentum Stocks to Buy for November 22nd
by Zacks Equity Research
BWAY, RIGL and BROS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 22, 2023.
New Strong Buy Stocks for November 22nd
by Zacks Equity Research
RIGL, BWAY, AVDX, IMGN and EAT have been added to the Zacks Rank #1 (Strong Buy) List on November 22, 2023.